Search This Blog

Tuesday, March 17, 2026

Piper Sandler upgrades Tandem Diabetes Care to Overweight, raises price target to $33 from $21

 


  • Piper Sandler cites potential pharmacy pricing benefits as key driver for the Tandem Diabetes Care upgrade.
  • Firm also highlights international direct market opportunities as supporting the new $33 price target from $21.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)